Allurion Technologies, Inc. (ALUR) Stock Price & Analysis
Allurion Technologies, Inc. (ALUR) rose 0.34% to USD 0.74 as of June 10, 2026 at 03:32 UTC, according to Nexqual real-time market data.
ALUR last closed at USD 0.74; the session ranged USD 0.74–0.85 on volume of 8,085 shares. Market capitalization is $11.14M, with a 52-week range of USD 0.23–3.33 (OQB). Source: Nexqual, June 10, 2026 at 03:32 UTC.
Key Statistics (as of June 10, 2026 at 03:32 UTC)
| Price | USD 0.74 |
|---|---|
| Change | ▲ 0.34% (up) |
| Previous Close | USD 0.74 |
| Open | USD 0.74 |
| Day Range | USD 0.74 – 0.85 |
| 52-Week Range | USD 0.23 – 3.33 |
| Volume | 8,085 shares |
| Market Cap | $11.14M |
| Exchange | OQB |
Technical Analysis (ALUR)
Nexqual's technical model rates ALUR "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 03:32 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.38 (neutral) |
| vs SMA50 | Below (USD 0.78) |
| MACD | 0 (positive) |
Analyst Ratings (ALUR)
Wall Street analysts rate ALUR "None" based on 2 analysts, with a mean price target of USD 5.5 (range USD 3–8), per Nexqual as of June 10, 2026 at 03:32 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 5.5 |
| High Target | USD 8 |
| Low Target | USD 3 |
Earnings (ALUR)
| Next Earnings Date | 2026-08-12 |
|---|---|
| Revenue Estimate | $3.30M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.46 vs est -0.34 ▼ miss |
| 2025-12-31 | USD -0.36 vs est -0.63 ▲ beat |
| 2025-09-30 | USD -1.18 vs est -2.45 ▲ beat |
| 2025-06-30 | USD -0.87 vs est -0.89 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
Financials & Fundamentals (ALUR)
| Total Revenue | $12.60M |
|---|---|
| Revenue Growth (YoY) | -47.20% |
| Gross Margin | +52.70% |
| Operating Margin | -126.60% |
| Profit Margin | -264.74% |
| Current Ratio | 0.3 |
| Total Cash | $5.06M |
| Total Debt | $78.25M |
| Free Cash Flow | $-13.37M |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
Financial Health Score (ALUR)
Nexqual rates Allurion Technologies, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:32 UTC.
| Growth | Critical — Revenue -53% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $5M cash vs $78M debt |
| Cash Flow | Weak — FCF negative: -$13M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ALUR)
| Insider Ownership | +5.18% |
|---|---|
| Institutional Ownership | +1.18% |
| Shares Outstanding | 15.01M |
| Float | 14.70M |
| Short % of Float | +5.17% |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
Leadership (ALUR)
Allurion Technologies, Inc. is led by Shantanu K. Gaur (age 38), Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director, per Nexqual as of June 10, 2026 at 03:32 UTC.
| Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director | Shantanu K. Gaur (age 38) |
|---|---|
| Chief Operating Officer | Ojas A. Buch (age 51) |
| Vice President of Global Marketing | Alexandra van der Stap |
| Vice President of International Sales & Marketing | Laurent Laffineur |
Major Backers & Investors (ALUR)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.27% |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
From Allurion Technologies, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Allurion Technologies Inc. focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally.
- Its Allurion Program platform offers the Allurion Smart Capsule, a swallowable and procedure-less intragastric balloon for weight loss, and access to the Allurion Virtual Care Suite, a digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVNI | Nvni Group Limited | USD 1 | ▼ 1.96% |
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
| ACON | Aclarion, Inc. | USD 3.26 | ▼ 8.68% |
| HWH | HWH International Inc. | USD 1.23 | ▲ 17.79% |
| DWTX | Dogwood Therapeutics, Inc. | USD 1.45 | ▼ 3.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:32 UTC. This page is informational and not investment advice.